Accenture estimates, target upped at Goldman
ACN estimates were boosted through 2013, Goldman Sachs said. Company is realizing higher sales and margins. Buy rating and new $62 price target.
-----
Apple estimates boosted at Jefferies
AAPL estimates were upped through 2012, Jefferies said. iPhone strength should offset any iPad cuts. Buy rating and $500 price target.
-----
Apple estimates increased at Needham
AAPL estimates were raised through 2012, Needham said. Mac and iPad sales should drive growth.
-----
Assured Guaranty estimates cut at UBS
AGO estimates lowered through 2011, UBS said. Lower discount rates on loss reserves. Maintain $28 price target and Buy rating.
-----
Biomarin Pharmaceuticals upgraded at Deutsche
BMRN was upgraded from Hold to Buy, Deutsche Bank said. $40 price target. Company has a promising pipeline and multiple near-term catalysts.
-----
Boston Scientific target reduced at Goldman
Shares of BSX now seen reaching $6.70, according to Goldman Sachs. Consensus sales expectations appear too high. Neutral rating.
-----
Charles Schwab estimates lowered at JMP
SCHW estimates were cut through 2012, JMP Securities said. Company is realizing lower asset fees and net interest income. Market Perform rating.
-----
Comerica upgraded at Wells
CMA was upgraded from Underperform to Market Perform, Wells Fargo said. Valuation call, as the stock is down 22% over the past 7 weeks.
-----
ConocoPhillips estimates increased at UBS
COP estimates increased through 2012, UBS said. Shutting down unprofitable refinery. Maintain $64 price target and Neutral rating.
-----
Coventry Health estimates increased at Morgan Stanley
CVH estimates were raised through 2013, Morgan Stanley said. $39 price target. Company is cutting costs and looking to expand its Medicaid business in Kentucky. Overweight rating.
-----
Equity One estimates cut at UBS
EQY estimates cut through 2012, UBS said. Reflecting dilution from sale to Blackstone. Maintain $18 price target and Neutral rating.
-----
Huntington Ingalls rated new Sell at Goldman
HII was initiated with a Sell rating, Goldman Sachs said. $21 price target. Company is leveraged to a shrinking U.S. defense budget.
-----
Jabil Circuit estimates, target raised at Citigroup
Shares of JBL now seen reaching $22, according to Citigroup. Estimates also raised on impressive ability to perform in tough macro. Maintain Hold rating.
-----
Jabil Circuit estimates, target raised at UBS
Shares of JBL now seen reaching $22, according to UBS. Estimates also raised on better than expected results in DMS and HVS segments. Maintain Buy rating.
-----
KLA-Tencor rated new Neutral at JP Morgan
KLAC was initiated with a Neutral rating, JP Morgan said. Company has solid margins, but exposure to foundry customers. $43 price target.
-----
Lam Research rated new Overweight at JP Morgan
Coverage of LRCX was started with an Overweight rating, JP Morgan said. $56 price target. Company will likely repurchase a lot of its shares.
-----
Masco upgraded at UBS
MAS was upgraded from Sell to Neutral, UBS said. $7.50 price target. Impact of weaker macro backdrop already reflected in valuation.
-----
Mead Johnson Nutrition Company downgraded at Citigroup
MJN was downgraded from Buy to Hold, Citigroup said. $80 price target. Valuation call as stock has limited upside.
-----
Mead Westvaco upgraded at JP Morgan
MWV was upgraded from Neutral to Overweight, JP Morgan said. $30 price target. Company is a defensive play an offers a solid dividend yield.
-----
Mylan rated new Hold at Canaccord
MYL was initiated with a Hold rating, Canccord said. $21 price target. Near term earnings risk tempers otherwise upbeat view.
-----
Novellus Systems rated new Overweight at JP Morgan
NVLS was initiated with an Overweight rating, JP Morgan said. $35 price target. Memory business should continue to drive growth and the company will likely return cash to shareholders.
-----
Oneok estimates, target raised at Morgan Stanley
Shares of OKE now seen reaching $82, according to Morgan Stanley. Estimates also increased, given increased growth visibility. Equal-weight rating.
-----
Paccar estimates, target cut at Credit Suisse
PCAR estimates were reduced through 2013, Credit Suisse said. Truck sales should be slower in Europe. Neutral rating and new $39 price target.
-----
Perrigo rated new Hold at Canaccord
PRGO was initiated with a Hold rating, Canaccord said. $105 price target. Solid defensive play in a tough tape, but reflected in the stock price already.
-----
Perrigo estimates, target raised at Goldman
Shares of PRGO now seen reaching $110, according to Goldman Sachs. Estimates also increased, as the company is realizing higher margins. Neutral rating.
-----
Perrigo estimates, target raised at UBS
Shares of PRGO now seen reaching $115, according to UBS. Estimates also raised as double digit earnings growth seems achievable. Maintain Buy rating.
-----
Philip Morris estimates, target cut at Citigroup
Shares of PM now seen reaching $68, according to Citigroup. Estimates also lowered on F/X headwinds. Maintain Hold rating.
-----
Polo Ralph Lauren downgraded at Citigroup
RL was downgraded from Buy to Hold, Citigroup said. $160 price target. Ongoing inflation concerns and valuation.
-----
Qualcomm estimates increased at Sterne Agee
QCOM estimates were raised through 2013, Sterne Agee said. Company is well positioned for customers' new product launches. Buy rating and $67 price target.
-----
Silgan rated new Neutral at JP Morgan
SLGN was initiated with a Neutral rating, JP Morgan said. Valuation call, based on a $44 price target.
-----
Smithfield Foods upgraded at BMO
SFD was upgraded from Market Perform to Outperform, BMO Capital said. $24 price target. Stock is already factoring in lower hog prices.
-----
Sysco rated new Underperform at Credit Suisse
Coverage of SYY was started with an Underperform rating, Credit Suisse said. $23 price target. Growth is maturing and consensus estimates appear to optimistic.
-----
Teva Pharmaceutical rated new Buy at Canaccord
TEVA was initiated with a Buy rating, Canccord said. $52 price target. See an inflection point in 2012 on all fronts with sentiment at its lows.
-----
Texas Instruments estimates upped at Evercore
TXN estimates were boosted through 2012, Evercore Partners said. NSM purchase should add to earnings. Overweight rating and $33 price target.
-----
Walgreens estimates cut at Morgan Stanley
WAG estimates were reduced through 2013, Morgan Stanley said. Express Scripts exit continues to weigh on results. Overweight rating and $45 price target.
-----
Watson Pharmaceuticals rated new Buy at Canccord
WPI was initiated with a Buy rating, Canccord said. $85 price target. Solid pipeline with near term catalysts.
